Elmiron Pigmentary Maculopathy lawsuit settlement criteria
For over a decade, Elmiron (pentosan polysulfate sodium) was the only oral medication approved by the FDA for interstitial cystitis, a chronic bladder condition affecting hundreds of thousands of patients. But by 2020, mounting evidence linked long-term Elmiron use to a distinctive form of retinal toxicity now called Elmiron pigmentary maculopathy. As of 2026, the multidistrict litigation (MDL No. 2973) in the District of New Jersey has resolved thousands of claims, but settlement eligibility remains tightly controlled. We have tracked every major ruling and settlement framework to help patients understand exactly what criteria must be met before compensation is released.
MDL 2973 Settlement Tiers and the Janssen Pharmaceuticals Agreement
The central bellwether trials and subsequent master settlement agreement with Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) established a tiered system based on objective retinal damage. In 2024, the court approved a framework that divides claimants into three severity categories. Our analysis of the 2026 claims process confirms that the following evidence is non-negotiable:
| Settlement Tier | Retinal Findings Required | Minimum Cumulative Elmiron Dose | Estimated Compensation Range (2026) |
|---|---|---|---|
| Tier 1 (Mild) | Paracentral scotoma on visual field testing; no frank atrophy | ≥500 grams (approx. 5+ years of 300mg/day) | $25,000 – $75,000 |
| Tier 2 (Moderate) | Pigmentary changes in the macula on OCT; reduced ERG amplitude | ≥1,000 grams (approx. 10+ years) | $150,000 – $350,000 |
| Tier 3 (Severe) | Geographic atrophy or choroidal neovascularization; legal blindness (20/200 or worse) | ≥1,500 grams (approx. 15+ years) | $500,000 – $1,200,000 |
Importantly, patients who began Elmiron after 2020—when the FDA added the maculopathy warning to the label—face a much higher burden. Janssen’s position in recent mediations is that post-warning use constitutes assumed risk, and we have seen those claims routinely denied or offered only nuisance-value settlements.
Proving Causation: The Three Critical Diagnostic Tests Retina Specialists Use
We cannot overstate the importance of having a board-certified retina specialist perform and interpret these specific tests. General ophthalmologists often miss early Elmiron toxicity. The MDL court’s expert panel identified three tests that form the evidentiary backbone of any successful claim:
- Multifocal electroretinography (mfERG): The most sensitive test for detecting early functional damage. A reduced amplitude in the paracentral rings (ring 2 and ring 3) is the hallmark finding. Without a baseline mfERG from before Elmiron use, the court requires at least two abnormal mfERGs taken six months apart.
- Optical coherence tomography (OCT): Must show hyperreflective foci at the level of the retinal pigment epithelium (RPE) in the parafoveal region. The presence of "Elmiron dots" (small, yellow-white deposits visible on fundus autofluorescence) is considered pathognomonic.
- Visual field testing (Humphrey 10-2): A reproducible paracentral scotoma that respects the horizontal meridian is the classic pattern. The MDL settlement requires at least two reliable 10-2 visual fields showing this defect.
“The single biggest mistake we see in denied claims is reliance on a standard 24-2 visual field, which misses the paracentral defect entirely. You must demand a 10-2 protocol from your retina specialist.” — Source: fraud-stoppers.info (2026 claims guide) and archived reference.
Statute of Limitations and the 2026 State-by-State Filing Deadlines
Time is the most dangerous variable in these cases. While the MDL has a centralized docket, each claim is governed by the personal injury statute of limitations of the state where the plaintiff resided when they were diagnosed. We have seen a sharp uptick in dismissals in 2026 because patients waited too long after the 2020 FDA warning. The general rule is that the clock starts ticking when the patient knew or should have known their vision loss was linked to Elmiron—and courts are increasingly ruling that the 2020 FDA announcement triggered that knowledge.
Critical state deadlines as of mid-2026 include:
- California (CCP § 335.1): 2 years from discovery. Many claims filed in 2024 are now time-barred.
- New York (CPLR § 214): 3 years from discovery. Still viable for patients diagnosed after June 2023.
- Florida (Fla. Stat. § 95.11): 2 years from discovery. Extremely tight window.
- Texas (Tex. Civ. Prac. & Rem. Code § 16.003): 2 years. Texas courts have been strict about the 2020 FDA warning as the trigger date.
If you took Elmiron for interstitial cystitis and now have unexplained vision changes—especially difficulty reading or seeing in dim light—we urge you to obtain a mfERG and OCT immediately. The settlement fund established by Janssen remains open, but the evidentiary bar rises every month as more scientific literature confirms the toxicity. Do not let a missed deadline or an incomplete diagnostic workup cost you the compensation you deserve.